Jefferies upgraded Azenta (AZTA) to Buy from Hold with a price target of $38, up from $30. The firm sees an attractive setup for the shares into 2026. The company has “healthy” biopharma exposure and “plenty of growth drivers” from innovation, pricing, attach rates and potential acquisitions, the analyst tells investors in a research note. Jefferies believes the shares can re-rate higher as investors gain confidence in Azenta’s mid-term opportunity.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off